- Company
- Pfizer seeks for approval on NSCLC drug ‘lorlatinib’
- by Kim, Jin-Gu Oct 12, 2020 06:15am
- Pfizer has taken a first step to launch a non-small cell lung cancer (NSCLC) treatment ‘lorlatinib’ in the South Korean market. According to a pharmaceutical industry source on Oct. 7, Pfizer Pharmaceutical Korea has recently submitted an application to the Ministry of Food and Drug Safety (MFDS) to request an item approval on lorlatin
- Policy
- Pharmaceutical reimbursement standards should be updated
- by Lee, Hye-Kyung Oct 12, 2020 06:13am
- It has been argued that the government should be active from screening for osteoporosis to creating a continuous treatment environment and establishing an integrated treatment system for preventing fractures in stages. On the 7th, Bong-min Jeon, a member of People Power Party (Health and Welfare Committe, Suyeong-gu, Busan), published a na
- Policy
- 'Abortion' within 14 weeks of pregnancy is allowed
- by Lee, Tak-Sun Oct 12, 2020 06:13am
- As the government allowed abortions in early pregnancy in accordance with the Constitutional Court's ruling against the constitution of abortion, it also decided to permit spontaneous abortion inducing medicines. Accordingly, it is noteworthy whether 'Mifegyne', which is widely used overseas, will be officially introduced in Korea. The gov
- Policy
- Dupixent targeting atopic dermatitis was launched
- by Lee, Tak-Sun Oct 8, 2020 06:25am
- Since the first biological drug Dupixent targeting atopic dermatitis was launched in Korea, other foreign-funded pharmaceutical companies are also developing new drugs. There are four clinical trials approved in Korea this year. On the 6th, the MFDS approved the phase III clinical trial protocol of Lebrikizumab. It is evaluated for effica
- InterView
- Pfizer in the center of autoimmune disease treatment scene
- by Eo, Yun-Ho Oct 8, 2020 06:24am
- Shifting the paradigm in autoimmune disease, tumor necrosis factor (TNF)-α inhibitors have taken root as major treatment option not only for rheumatoid arthritis, but also for other various areas including ankylsoing spondylitis, psoriasis, and psoriatic arthritis. Regardless, there are still patients struggling with unmet needs as they
- Policy
- The bioequivalence test of Lixiana's generic has begun
- by Lee, Tak-Sun Oct 8, 2020 06:23am
- The development of a generic for Lixiana (Edoxaban, Daiichi Sankyo Korea), which was released as the latest among new oral anticoagulants (NOAC), has begun. Lixiana was approved six years later than the country's first NOAC drug, Xarelto (Rivaroxaban, Bayer Korea), but it is currently recording the highest sales performance in the market.
- Company
- Roche Diagnosis provides COVID-19 customized diagnostic test
- by Oct 8, 2020 06:23am
- Roche Diagnostics Korea, which celebrates its 30th anniversary, has promised to provide rapid diagnostic tests in the pendemic. On the 6th, Roche Diagnostics Korea held an online press conference to commemorate the 30th anniversary of its founding, highlighting the value of diagnosis and the role of Roche Group in the situation of COVID-19.
- Policy
- 17 new drugs including Verzenio got to expand coverage
- by Kim, Jung-Ju Oct 8, 2020 06:23am
- Apparently, total 13 new drugs have been listed for healthcare reimbursement this year. Total four already-listed drugs had their reimbursement expanded with the coverage enhancement policy. The record demonstrates the social consensus has flexibly expanded healthcare coverage even on expensive drug for a limited patient size. Daily Pharm su
- Company
- MSD on final stretch with Keytruda coverage expansion
- by Eo, Yun-Ho Oct 7, 2020 06:09am
- MSD Korea made the last move for the Keytruda coverage expansion. Now it is back to the government’s turn to make the decision. Related industry sources confirmed, MSD has submitted the final financial expense sharing plan to Health Insurance Review and Assessment Service (HIRA) after revising the detailed strategies regarding the reim
- Company
- When will the Zyprexa lawsuit for damages be concluded?
- by Kim, Jin-Gu Oct 7, 2020 06:09am
- Interest is focused on whether the lawsuit for Zyprexa (Olanzapine) could be completed within this year. The range of compensation for patent infringement is determined according to the decision of the Supreme Court. If the Supreme Court sided with the original company Lilly Korea, it would be an obstacle to the early release of generics by d
